Isavuconazonium Sulfate
- TRADE NAME: Cresemba (Astellas)
- INDICATIONS: Invasive aspergillosis, mucormycosis
- SYNONYM: Isavuconazole
- CLASS: Antifungal / antimycotic, Antifungal; triazole, Antimicrobial
- HALF-LIFE: 130 hours
FDA APPROVAL DATE: 03/06/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Carbamazepine, Ketoconazole, Rifampin, Ritonavir, St John's Wort, Strong CYP3A4 inducers or inhibitors
PREGNANCY CATEGORY: C
Isavuconazonium sulfate is the water-soluble prodrug of isavuconazole.
Contra-indicated in patients with familial short QT syndrome.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric